Eoin P. Flanagan, M.B., B.Ch.

Closed for Enrollment

• A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Rochester, Minn.

  To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

• A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or In Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) (MOGAD) Rochester, Minn.

  The purpose of this study is to evaluate the effectiveness, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as monotherapy or in addition (add-on) to baseline/background ISTs for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) relapse prevention.

   

• A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) (cosMOG) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purpose of the study is to evalute the effectiveness, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).